We are international
Donate
TEXT SIZE   


Sydney 2005: Lack of Mcl-1 Confers Resistance to Bortezomib and Melphalan but not Doxorubicin
By Steven Le Gouill
04.14.05
Dr. Le Gouill concluded the final focus session with a discussion on bortezomib and Mcl-1. As mentioned throughout this session, resistance to novel agents, such as bortezomib, is unknown. Mcl-1 is an antiapoptotic protein that protects MM cells against spontaneous and dexamethasone-induced apoptosis. His study investigated the role of Mcl-1 in bortezomib-induced apoptosis in comparison to conventional therapies doxorubicin and melphalan. His analyses suggest that bortezomib and melphalan, but not doxorubicin, triggers Mcl-1-dependent-induced apoptosis pathways. His study demonstrates that Mcl-1 may be an important mediator of bortezomib and melphalan-induced apoptosis.


Back to session summary


 related articles